2B30 Stock Overview
A biopharmaceutical company, engages in developing and commercializing therapies in Illinois. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Xeris Biopharma Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.25 |
| 52 Week High | US$3.25 |
| 52 Week Low | US$1.58 |
| Beta | 1.24 |
| 11 Month Change | 12.63% |
| 3 Month Change | 41.50% |
| 1 Year Change | 89.82% |
| 33 Year Change | 84.43% |
| 5 Year Change | n/a |
| Change since IPO | 80.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2B30 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 12.2% | -1.5% | 1.5% |
| 1Y | 89.8% | -19.6% | 8.8% |
Return vs Industry: 2B30 exceeded the German Pharmaceuticals industry which returned -19.6% over the past year.
Return vs Market: 2B30 exceeded the German Market which returned 8.8% over the past year.
Price Volatility
| 2B30 volatility | |
|---|---|
| 2B30 Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2B30 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 2B30's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 377 | John Shannon | www.xerispharma.com |
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies.
Xeris Biopharma Holdings, Inc. Fundamentals Summary
| 2B30 fundamental statistics | |
|---|---|
| Market cap | €479.05m |
| Earnings (TTM) | -€60.00m |
| Revenue (TTM) | €178.12m |
2.7x
P/S Ratio-8.0x
P/E RatioIs 2B30 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2B30 income statement (TTM) | |
|---|---|
| Revenue | US$187.36m |
| Cost of Revenue | US$34.92m |
| Gross Profit | US$152.44m |
| Other Expenses | US$215.55m |
| Earnings | -US$63.11m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 81.36% |
| Net Profit Margin | -33.69% |
| Debt/Equity Ratio | -816.6% |
How did 2B30 perform over the long term?
See historical performance and comparison